Last viewed: ATNX

Prices are updated after-hours

ATNX Nasdaq

Athenex, Inc.

ATNX | $0.2031 -7.78% 1.9M

|

Health Technology

(0.0% 1d) (0.0% 1m) (-83.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (199.02% volume)
Earnings Calendar: 2022-10-27
Market Cap: $ 1,759,498
http://www.athenex.com
Sec Filling | Patents | 574 employees

(US) Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

cancer tirbanibulin treatment

add to watch list Paper trade email alert is off

Press-releases

Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen
Published: 2023-09-13 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| -13.74% | O: 2.14% H: 0.0% C: -1.3%
INAB | $1.025 -0.49% -0.49% 220K

|

| 6.33% | O: 1.01% H: 3.23% C: -1.05%
BMEA | $10.86 0.09% 0.09% 600K

|

Professional, Scientific, and T...

| -26.85% | O: 0.24% H: 0.0% C: -2.96%
SNY | News | $47.125 1.78% 1.75% 2.1M

|

Health Technology

| -14.67% | O: 0.26% H: 0.74% C: 0.33%
DTIL | $9.85 1.13% 1.12% 47K

|

Health Technology

| 2152.21% | O: -0.19% H: 4.62% C: -2.14%
KYMR | $34.37 1.18% 1.16% 420K

|

Health Technology

| 76.88% | O: 0.51% H: 1.74% C: -0.72%
INCY | $51.92 -0.82% -0.83% 1.8M

|

Health Technology

| -17.72% | O: 0.1% H: 1.09% C: 0.51%
CLLS | News | $2.64 3.53% 3.41% 24K

|

Health Technology

| 50.0% | O: 0.57% H: 0.56% C: -3.39%
BEAM | $24.13 0.96% 0.95% 2.1M

|

Health Technology

| -3.72% | O: 0.56% H: 1.15% C: -0.12%
companies leukemia market

Esophageal Cancer Market to Proliferate at a CAGR of 5.9% During the Study Period (2019-2032), Estimates DelveInsight
Published: 2023-07-06 (Crawled : 21:00) - prnewswire.com
ATNXQ | $0.0152 -85.53% 3.6K

|

| -86.19% | O: 54.31% H: 0.0% C: -29.37%
LLY | News | $731.33 0.69% 0.0% 2.3M

|

Health Technology

| 57.88% | O: -0.19% H: 0.28% C: -2.22%
XNCR | $18.19 -1.03% -1.04% 490K

|

Health Technology

| -22.77% | O: 0.17% H: 0.72% C: -0.97%
SNY | News | $47.125 1.78% 1.75% 2.1M

|

Health Technology

| -11.13% | O: -0.51% H: 0.0% C: 0.0%
LPTX | $3.17 13.21% 11.67% 330K

|

Health Technology

| 1.1% | O: -0.79% H: 6.03% C: -0.63%
INCY | $51.92 -0.82% -0.83% 1.8M

|

Health Technology

| -17.4% | O: -0.14% H: 0.16% C: -1.12%
ICLR | News | $298.15 3.44% 3.33% 720K

|

Health Technology

| 25.48% | O: 0.05% H: 0.64% C: -0.47%
CRIS | $14.6 2.03% 1.99% 21K

|

Health Technology

| 1659.27% | O: 1.29% H: 5.24% C: -5.26%
BCEL P | $0.077 0.0% 14K

|

Health Technology

| -90.43% | O: -1.1% H: 7.53% C: 5.06%
cancer study market

Delisting of Securities of Puhui Wealth Investment Management Co., Ltd.; National Energy Services Reunited Corp.; Bed Bath & Beyond Inc.; IMV Inc.; Celyad Oncology SA; Aptinyx Inc.; Athenex, Inc.; Greencity Acquisition Corporation; QualTek Services Inc.; Bellicum Pharmaceuticals, Inc.; Wejo Group Limited; Cyxtera Technologies, Inc.; HTG Molecular Diagnostics, Inc.; Unico American Corporation; PolarityTE, Inc.; Oncorus, Inc.; and OncoSec Medical Incorporated from The Nasdaq Stock Market
Published: 2023-07-06 (Crawled : 20:00) - globenewswire.com
ONCSQ | $0.0001 43900.0% 820

|

| -99.89% | O: -15.79% H: 12.5% C: -6.25%
CYXTQ | $0.0007 -57.14% 1.8K

|

| -98.71% | O: -4.89% H: 17.73% C: -5.28%
QTEKQ | $0.012 125.0% 640K

|

| -36.36% | O: -17.88% H: 11.07% C: -0.37%
ATNXQ | $0.0152 -85.53% 3.6K

|

| -86.19% | O: 54.31% H: 0.0% C: -29.37%
IMVIQ | $0.0001 36400.0% 6K

|

| -100.0% | O: -18.75% H: 192.31% C: 32.62%
ONCR | $0.126 -75.95% 140K

|

Health Technology

| 196.13% | O: -2.05% H: 29.3% C: 0.0%
NESR | $9.0 -36.31% 150K

|

Industrial Services

| 206.67% | O: 0.0% H: 0.0% C: 0.0%
NDAQ | $61.22 1.44% 1.42% 2.1M

|

| 24.92% | O: -0.22% H: 0.8% C: 0.18%
BLCM | $0.0748 381.28% 6.1K

|

Health Technology

| -79.78% | O: -14.11% H: 7.11% C: 6.2%
management nasdaq energy services beyond group acquisition medical molecular market

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
Published: 2023-05-14 (Crawled : 16:20) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M

|

Health Technology

| Email alert Add to watchlist
sales agreement

Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO
Published: 2023-05-01 (Crawled : 17:00) - prnewswire.com
ATNX | $0.2031 -7.78% 1.9M

|

Health Technology

| -84.13% | O: 1.56% H: 7.69% C: 2.31%
quantum paclitaxel asco leap trial

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
Published: 2023-03-20 (Crawled : 13:20) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M

|

Health Technology

| -89.02% | O: -23.78% H: 0.0% C: 0.0%
business year update financial results

Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
Published: 2022-12-20 (Crawled : 13:20) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M

|

Health Technology

| 60.55% | O: 118.18% H: 8.7% C: -42.03%
quantum breast trial leap positive cancer

Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel
Published: 2022-12-20 (Crawled : 13:20) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M

|

Health Technology

| 60.55% | O: 118.18% H: 8.7% C: -42.03%
quantum trial leap positive

Athenex Announces Positive Results of Special Stockholder Meeting
Published: 2022-11-22 (Crawled : 16:00) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M

|

Health Technology

| 9.13% | O: 1.02% H: 0.0% C: 0.0%
meeting positive results

Athenex Announces Closing of the Sale of its China API Business
Published: 2022-11-21 (Crawled : 13:20) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M

|

Health Technology

| 6.89% | O: 3.42% H: 0.0% C: -5.29%
china

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001209191-23-027951	4	2023-05-08	2023-05-05	Buy	A	8382	250397

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

75%

25%

Top 10 Gainers

MTTR | News M | $4.78 174.71% 63.6% 72M

|

AGBA | $2.565 105.2% 51.27% 200M

|

MLEC | $2.44 74.29% 42.62% 78M

|

EDBL | News | $6.28 67.02% 40.13% 16M

|

ATGL | $2.91 48.81% 32.8% 180K

|

ZAPP | $0.2175 47.16% 32.05% 16M

|

ONFO | $0.6075 38.38% 27.74% 7.3M

|

VIVK | $1.48 38.32% 27.7% 530K

|

Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.8M

|

SDIG A | $3.635 35.13% 26.0% 1M

|

Last 48 Hours Insiders Buying

MCFT P 26039 | $21.5 1.9% 1.86% 110K

|

Consumer Durables

| 00:00
YORW P 29 | $35.43 1.03% 1.02% 66K

|

| 19:01
VUZI P 14500 | $1.35 11.57% 10.37% 890K

|

Electronic Technology

| 17:00
BANF P 256 | $91.28 2.24% 2.18% 150K

|

| 15:30
RMCF | $3.56 0.28% 0.28% 11K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar